Table 3.
Median Survival and Predicted 1-, 2-, and 5-Year OS Rates According to Stage of MF/SS
| Stage | No. of Patients | OS |
DSS |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (months) | 95% CI (months) | IQR (months) | RM (months) | Rate (%) |
Median (months) | 95% CI (months) | IQR (months) | RM (months) | Rate (%) |
||||||
| 1 Year | 2 Years | 5 Years | 1 Year | 2 Years | 5 Years | ||||||||||
| IIB | 457 | 68.37 | 61.18 to NR | 31.0-NR | 59.5 | 88.50 | 80.10 | 57.40 | NR | NA | 42.2-NR | 66.5 | 93.10 | 86.40 | 67.47 |
| III (all)* | 320 | NR | 57.76 to NR | 36.8-NR | 60.9 | 89.50 | 79.50 | 58.20 | NR | NA | 43.9-NR | 65.9 | 91.77 | 84.56 | 66.28 |
| IIIA | 187 | NR | 57.8 to NR | 35.2-NR | 61.7 | 89.60 | 79.80 | 60.20 | NR | NA | 43.9-NR | 66.5 | 91.95 | 83..89 | 68.26 |
| IIIB | 119 | 62.4 | 44.8 to NR | 32.8-NR | 58.2 | 88.50 | 77.80 | 55.70 | NR | NA | 44.8-NR | 65.4 | 93.22 | 86.77 | 66.12 |
| IVA (all)† | 463 | 47.5 | 43.0 to 56.10 | 22.3-NR | 50.9 | 87.60 | 73.20 | 42.90 | 63.4 | 49.8 to NR | 28.4-NR | 57.3 | 91.63 | 80.03 | 52.34 |
| IVA1 | 290 | 52.7 | 48.58 to 78.77 | 31.5-NR | 55.7 | 90.40 | 79.40 | 48.30 | 66.2 | 50.9 to NR | 38.5-NR | 60.8 | 93.41 | 85.39 | 55.98 |
| IVA2 | 127 | 29 | 23.7 to 44.4 | 13.6-68.7 | 40.4 | 81.00 | 59.60 | 32.90 | 44.4 | 27.2 to NR | 20.1-NR | 48.9 | 87.27 | 69.20 | 44.36 |
| IVB | 35 | 33.3 | 15.91 to NR | 14.0-NR | 42.5 | 78.50 | 54.30 | 39.00 | 33.3 | 15.9 to NR | 4.0-NR | 44.1 | 78.54 | 54.28 | 39.04 |
| All stages | 1,275 | 63 | 55.67 to 69.0 | 25.4-NR | 56.3 | 88.10 | 76.60 | 51.90 | NR | 68.0 to NR | 34.7-NR | 62.6 | 91.79 | 82.59 | 61.03 |
Abbreviations: DSS, disease-specific survival; IQR, interquartile range; MF, mycosis fungoides; NR, not reached; OS, overall survival; RM, restricted mean; SS, Sézary syndrome.
*
For 14 patients, data were not available to determine whether stage was IIIA or IIIB.
†
For 46 patients, data were not available to determine whether stage was IVA1 or IVA2.